Merck Sharp & Dohme Ltd, which is the UK subsidiary of Merck & Co, has withdrawn its marketing authorisation application for the cancer treatment, Vorinostat MSD (vorinostat) from the European Medicines Agency. ---Subscribe to MedNous to access this article--- Regulation & Policy
